Compare GE Vernova Inc (GEV) vs Eli Lilly And Co (LLY) Price & Performance

GE Vernova (GEV) trades at $997.09, down 3.12% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical signals with support at $985 and resistance at $1,005. Recent Q1 2026 earnings beat expectations with $17.44 EPS, though Q2 missed. The company secured the first US construction permit for its BWRX-300 SMR, strengthening its nuclear pipeline amid growing AI-driven power demand.

Outlook remains positive with 2026 revenue projected at $41.4B and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and execution challenges in the wind segment. The stock offers 27% upside to consensus target, supported by strong institutional sentiment and AI infrastructure tailwinds.

Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.

Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.